期刊文献+

冠脉内注射高剂量替罗非班对急性ST段抬高型心肌梗死直接PCI术后碎裂QRS波的影响 被引量:3

Effect of intracoronary injection of high-dose tirofiban on fragmented QRS complexes in patients with acute ST segment elevation myocardial infarction after primary percutaneous coronary intervention
原文传递
导出
摘要 目的探讨冠脉内注射高剂量替罗非班对急性ST段抬高型心肌梗死(STEMI)直接经皮冠状动脉介入(PCI)治疗术后体表心电图出现碎裂QRS波(f QRS)的影响。方法连续入选150例接受直接PCI治疗的急性STEMI患者,随机分成冠脉内注射高剂量替罗非班组(替罗非班组,n=75)和常规治疗组(n=75),观察住院48 h内体表心电图f QRS的发生率以及术后住院期间主要不良心脏事件(MACE)。结果两组临床基本特征无显著差别。替罗非班组术后校正的TIMI帧数(CTFC)较常规组少[(23±7)帧vs.(30±10)帧,P<0.05];肌酸激酶同工酶(CK-MB)峰值浓度显著低于常规治疗组[(245±162)U/L vs.(311±180)U/L,P<0.05],而左心室射血分数(LVEF)值则显著高于常规治疗组[(51±6)%vs.(47±7)%,P<0.05],同时,术后替罗非班组和常规治疗组f QRS发生率分别41%(30/75)和57%(43/75),两组之间比较差异显著,P<0.05)。两组住院期间MACE事件有差异,但未达到统计学意义(5%vs.12%)。结论冠脉注射高剂量替罗非班能改善心肌灌注,降低术后体表心电图f QRS发生率,提高心脏功能。 AIM To investigate the effect of intracoronary injection high-dose tirofibann on the fragmented QRS complexes (fQRS) in patients with acute ST segment elevation myocardial infarction (STEM) after primary percutaneous coronary intervention (PCI). METHODS One hundred fifty acute STEMI patients enrolled continuously in the study were divided into high-dose tirofiban group (tirofiban group) and routine treatment group (routine group). The changes of fQRS on electrocardiogram and the MACE events were observed within 48 hours after primary PCI. RESULTS A total of 150 patients (aged 35-83 years; male, 82.7%) were included in the study and the baseline clinical characteristics were comparable between the two groups. Compared with patients in routine group, patients in the tirofiban group had lower levels of creatine kinase-MB [(245±162) U/L vs. (311±180) U/L, P〈0.05] and corrected TIMI Frame Count (CTFC) post-PCI [(23±7) vs. (30±10), P〈0.05], but higher left ventricular ejection fraction (LVEF) [(51±6)% vs. (47±7)%, P〈0.05]. The incidence of presence of fQRS on electrocardiogram in tirofiban group was lower than that in routine group (41% (30/75) vs. 57% (43/75), P〈0.05). In Spearman’s correlation analysis, the level of CK-MB showed positive correlation with the number of leads with fQRS (r=0.207, P〈0.05), but LVEF showed negative correlation with the number of leads with fQRS (r=-0.242, P〈0.01). Multivariate analysis revealed that the intracoronary injection of high-dose tirofiban was the negative predictor of fQRS (Wald=4.257, OR: 0.364, 95% CI 0.139-0.95, P〈0.05). There were differences in MACE events between the two groups during hospitalization, but the differences were not statistically significant (5.3% to 12%. t=3.63). CONCLUSION High-dose intracoronary injection of tirofiban can help to improve myocardial perfusion, reduce postoperative the presence of fQRS appearing on the standard 12-lead ECG and enhance cardiac functions.
出处 《心脏杂志》 CAS 2017年第5期563-566,共4页 Chinese Heart Journal
关键词 替罗非班 冠状动脉内注射 碎裂QRS波 直接PCI tirofiban intracoronary injection fragmented QRS complexes primary percutaneous coronary intervention
  • 相关文献

参考文献3

二级参考文献23

  • 1杨新春,张大鹏,王乐丰,徐立,葛永贵,王红石,李惟铭,倪祝华,夏昆,连勇,薛永利,马利祥.冠状动脉内应用国产替罗非班对急性ST段抬高心肌梗死急诊介入治疗后心肌灌注和临床预后的影响[J].中华心血管病杂志,2007,35(6):517-522. 被引量:73
  • 2Collaborative Research Group of Reperfusion Therapy in Acute Myocardial Infarction.重组葡激酶与重组组织型纤溶酶原激活剂治疗急性心肌梗死的随机多中心临床试验[J].中华心血管病杂志,2007,35(8):691-696. 被引量:43
  • 3Boersma E, Harrington RA, Moliterno D J, et al. Platelet glycoprotein Ⅱ b/Ⅲ a inhibitors in acute coronary syndromes:a meta-analysis of all major randomised clinical trials.Lancet,359:189-198.
  • 4Steinhubl SR, Talley JD, Braden GA, et al. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention:results of the GOLD (AU-Assessing Ultegra) multicenter study.Circulation,2001,103:2572-2578.
  • 5Batchelor WB, Tolleson TR, Huang Y, et al. Randomized comparison of platelet inhibition with abciximab,tirofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison of measurements of platelet aggregation with aggrastat,reopro,and eptifibatide.Circulation,2002,106:1470-1476.
  • 6Topol EJ,Moliterno DJ,Herrmann HC,et al.Comparison of two platelet glycoprotein Ⅱ b/Ⅲa inhibitors,tirofiban and abciximab,for the prevention of ischemic events with percutaneous coronary revascularization.N Engl J Med,2001,344:1888-1894.
  • 7Ernst NM,Suryapranata H,Miedema K,et al.Achieved platelet aggregation inhibition after different antiplatelet regimens during percutaneous coronary intervention for ST-segment elevation myocardial infarction.J Am Coll Cardiol,2004,44:1187-1193.
  • 8Danzi GB,Sesana M,Capuano C,et al.Comparison in patients having primary coronary angioplasty of abciximab versus tirofiban on recovery of left ventricular function.Am J Cardiol,2004,94:35-39.
  • 9Valgimigli M, Campo G,Percoco G,et al. Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction:the multistrategy randomized trial.JAMA,2008,299:1788-1799.
  • 10Valgimigli M,Percoco G,Malagutti P,et al. Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction:a randomized trial.JAMA,2005,293:2109-2117.

共引文献2036

同被引文献36

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部